Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis*

M.A. McAleer,1,2 I. Jakasa,3 G. Hurault,4 P. Sarvari,4 W.H.I. McLean,5 R.J. Tanaka4,6 S. Kezic6 and A.D. Irvine1,2,7

1National Children’s Research Centre and 2Paediatric Dermatology, Our Lady’s Children’s Hospital, Crumlin, Dublin 12, Ireland
3Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia
4Department of Bioengineering, Imperial College London, London, U.K.
5Dermatology and Genetic Medicine, University of Dundee, Dundee, U.K.
6Amsterdam UMC, University of Amsterdam, Corone Institute of Occupational Health, Amsterdam Public Health research institute, Meibergdreef 9, Amsterdam, the Netherlands
7Clinical Medicine, Trinity College Dublin, Dublin, Ireland

Linked Comment: Hijnen. Br J Dermatol 2019; 180:455–456.

Correspondence
Alan D. Irvine.
E-mail: irvinea@tcd.ie

Accepted for publication
18 July 2018

Funding sources
The group of A.D.I. is funded by the National Children’s Research Centre, Dublin, Ireland. M.A.McA. is supported by the National Children’s Research Centre, Dublin, Ireland. A.D.I. and W.H.I.M. are supported by the Wellcome Trust (090066/B/09/2 and 092530/Z/10/2). The Centre for Dermatology and Genetic Medicine, University of Dundee is supported a Wellcome Trust Strategic Award (098439/Z/12/Z to W.H.I.M.). We acknowledge the funding from the British Skin Foundation to R.J.T. and A.D.I. (021/SG/17). We acknowledge support from the CA COST Action CA16113 CliniMARK.

Conflicts of interest
None to declare.

*Plain language summary available online

DOI 10.1111/bjd.17088

Summary

Background Biomarkers of atopic dermatitis (AD) are largely lacking, especially in infant AD. Those that have been examined to date have focused mostly on serum cytokines, with few on noninvasive biomarkers in the skin.

Objectives We aimed to explore biomarkers obtainable from noninvasive sampling of infant skin. We compared these with plasma biomarkers and structural and functional measures of the skin barrier.

Methods We recruited 100 infants at first presentation with AD, who were treatment naive to topical or systemic anti-inflammatory therapies, and 20 healthy children. We sampled clinically unaffected skin by tape stripping the stratum corneum (SC). Multiple cytokines and chemokines and natural moisturizing factor were measured in the SC and plasma. We recorded disease severity and skin barrier function.

Results Nineteen SC and 12 plasma biomarkers showed significant differences between healthy and AD skin. Some biomarkers were common to both the SC and plasma, and others were compartment specific. Identified biomarkers of AD severity included T helper 2-skewed markers [interleukin (IL)-13, CCL17, CCL22, IL-5]; markers of innate activation (IL-18, IL-1α, IL1β, CXCL8) and angiogenesis (Flt-1, vascular endothelial growth factor); and others (soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, IL-16, IL-17A).

Conclusions We identified clinically relevant biomarkers of AD, including novel markers, easily sampled and typed in infants. These markers may provide objective assessment of disease severity and suggest new therapeutic targets, or response measurement targets for AD. Future studies will be required to determine whether these biomarkers, seen in very early AD, can predict disease outcomes or comorbidities.

What’s already known about this topic?
- Atopic dermatitis is a clinically heterogeneous condition with multiple clinical manifestations and a complex pathogenesis.
- Systemic biomarkers of severity have been identified in adults, but are less well defined in children.
- Biomarkers from the skin compartment have been based on biopsies to date.
Atopic dermatitis (AD) is the most common inflammatory skin disease, and the most common inflammatory disease of childhood. It affects up to 20% of children, and up to 10% of adults have a lifetime incidence of AD. The disease typically starts in infancy; in total 45% of all cases of AD begin within the first 6 months of life, 60% begin during the first year and 85% begin before 5 years of age. The importance of both a skin barrier defect and immune dysregulation in AD has been clearly demonstrated. Alterations and deficiencies in stratum corneum (SC) proteins, particularly filaggrin, and lipids have been implicated in the skin barrier deficiency. Several other pathogenic factors such as dysbiosis and epigenetic modulation of the disease have been identified, adding further layers of complexity. AD has a wide spectrum of clinical presentations, natural history, severity, therapeutic response and associated diseases.

There is generalized skin dysfunction in AD, with abnormalities in both affected and unaffected skin. Clinically unaffected skin has subclinical inflammation with skin barrier dysfunction, a proinflammatory cytokine milieu and lymphocytic infiltration. A chronic mild inflammation has been demonstrated in AD skin even in between flares. The role of type 2 immune activation in AD pathogenesis is well established; the T helper cell (Th)2 axis seems to be pathogenic across all subtypes of AD. However, increasing complexity in the immunopathogenesis of AD has become apparent, with activation of the Th22, Th17/interleukin (IL)-23 and Th1 cytokine pathways reported. Acute AD lesions have elevated Th2 and Th22 responses. In chronic AD lesions Th2 and Th22 responses are increased along with Th1 axis activation. Th17 levels have been shown to be upregulated in patients with both acute and chronic AD. IL-22 and IL-31 have also been identified as cytokines of interest, playing a role in epidermal hyperplasia and itch, respectively.

Despite AD being predominantly a disease of infancy and childhood, there are few studies investigating the paediatric immune profile. Paediatric and adult AD have clinical differences, including the distribution of lesions and microbiome abnormalities, differences that may point to pathomechanistic diversity. Paediatric studies have demonstrated a correlation between serum biomarkers and disease activity. Biomarkers include IL-31, CCL17, CCL22, CCL27, eosinophils and IgE. mRNA expression on DNA extracted from skin biopsies has been studied in paediatric AD.

Th2 expansion has been shown in peripheral blood in paediatric AD, without other polar T-cell subsets in the blood; in contrast, adult profiles showed Th2 and Th22 polarization. In infant skin there was a Th2 response but also innate and IL-17-related inflammation. Nonlesional, clinically unaffected skin in both adults and children has increased expression levels of cytokines with as high, or even higher levels in children compared with adults.

There is an ongoing need for therapeutic stratification of new and established treatments. Biomarker profiles will be central to this aim. As an example of this work, Thijs et al. reported biological heterogeneity in AD when they investigated biomarkers in adult patients, and demonstrated four unique clusters of biomarkers. Infantile AD is an important phenotype to characterize as it marks the commencement of the disease. Here we profiled both the plasma and SC in infants with AD. We analysed these biomarkers alongside eczema severity assessments and transepidermal water loss (TEWL). We identified clinically relevant biomarkers of AD severity, including novel markers, easily sampled and typed in infants.

**Patients and methods**

**Study population**

One hundred infants with AD were recruited, from November 2012 to November 2014, in a dedicated AD clinic in Our Lady’s Children’s Hospital, Dublin. A single, experienced paediatric dermatologist (M.A. McA.) assessed, recruited and treated all patients. Patients had to be < 12 months of age with moderate or severe AD, as determined by a Scoring Atopic Dermatitis
(SCORAD) score of \( \geq 25 \), for \( \geq 6 \) weeks’ duration. Furthermore, the patients had to be treatment naive, apart from the use of emollients and hydrocortisone 1% cream or ointment.

Twenty control patients were recruited when attending Our Lady’s Children’s Hospital, Dublin, for elective procedures under general anaesthetic. Patients were recruited if they did not have AD, any history suggestive of AD or any other inflammatory skin disease. All infants and children were examined to ensure an absence of inflammatory skin disease. All patients were asked to refrain from application of any topical agents for 24 h prior to assessment. The study was conducted in accordance with the Declaration of Helsinki and was approved by the research ethics committee of Our Lady’s Children’s Hospital, Dublin. Written informed consent was obtained from all patients’ parents.

**Clinical assessment**

The patients met the Hanifin and Rajka criteria for the diagnosis of AD.\(^3\) The age of onset of AD was recorded. Severity was assessed using the SCORAD scale.\(^4\) All patients had moderate or severe AD defined by SCORAD \( \geq 25 \). Objective SCORAD (oSCORAD) is derived from the SCORAD by not including subjective scores of parental assessment of sleep loss and itch.

**Stratum corneum transepidermal water loss measurement**

TEWL measurements were done under standardized conditions (room temperature of 22–25 °C and humidity levels of 30–35%). Patients were acclimatized for a minimum of 10 min, with their volar forearm skin exposed. Measurements were taken from an area of clinically unaffected skin on the volar forearm using the Tewameter 300 (Courage + Khazaka electronic GmbH, Cologne, Germany).

**Sampling of the stratum corneum by tape stripping**

The SC was sampled using the previously described method,\(^3\) using circular adhesive tape strips (3.8 cm\(^2\), D-Squame; Monaderm, Monaco) and a D-Squame pressure instrument D500 (CuDerm, Dallas, TX, U.S.A.). Eight consecutive tape strips were sampled, all from the same site, in nonlesional skin, 2 cm away from viable eczematous areas, and immediately stored at \(-80 \, ^\circ C\).

**Blood sampling**

Plasma was separated by centrifugation, pipetted into cryotubes and stored frozen at \(-80 \, ^\circ C\) until analysis.

**Determination of filaggrin breakdown products in the stratum corneum**

Natural moisturizing factor (NMF) component analysis (histidine, pyrrolidone carboxylic acid, trans- and cis-urocanic acid) and proteins was performed according to the method previously described.\(^5\)

**FLG genotyping**

All patients were screened for the nine most common filaggrin mutations found in the Irish population (R501X, Y2092X, 2282del4, R2447X, S3247X, R3419X, 3702X, S1040X and G1139X), as previously described.\(^6\)

**Cytokine analysis in tape strips and plasma samples**

Cytokine concentrations in the SC and plasma were measured using MESO QuickPlex SQ 120 (MSD, Rockville, MA, U.S.A.) according to the manufacturer’s instructions, apart from the samples being undiluted, and in the case of SC the sample incubation time was extended to 16 h.

Cytokines were measured on preconfigured multiplex panels, as follows. Proinflammatory panel: IL-1\(\beta\), IL-2 and IL-13 in the SC and additionally interferon-\(\gamma\), IL-4, IL-6, IL-10, IL-12p70 and tumour necrosis factor (TNF)-\(\alpha\) in plasma. Chemokine panel: CCL2, CCL3, CCL4, CCL13, CCL17, CCL22, CXCL8 and CXCL10 in the SC, and CCL5 and CCL11 in plasma. Cytokine panel: granulocyte–macrophage colony-stimulating factor (GM-CSF), IL-1\(\alpha\), IL-5, IL-7, IL-12p40, IL-15, IL-16 and IL-17A in the SC, and TNF-\(\beta\), IL-17A and vascular endothelial growth factor (VEGF) in plasma. Vascular panel: C-reactive protein, serum amyloid A (SAA), soluble intercellular adhesion molecule (sICAM)-1 and soluble vascular cell adhesion molecule (sVCAM)-1 in both SC and plasma. Angiogenesis panel: Flt-1, Tie-2, VEGF-A and VEGF-C in the SC, and basic fibroblast growth factor, placental growth factor and VEGF-D in plasma, as well as some singleplex assays (IL-18).

For statistical analysis, cytokine concentrations below the detection limit (but above the bottom of the curve) or above the detection limit were taken unchanged, and cytokine concentrations that were below the fit curve range (signal below the bottom of the bottom-of-the-curve fit, no concentration given) were assigned half the value of the lowest sample concentration below the detection limit to maintain the ranking order. The limits of detection are given in Table S1 (see Supporting Information).

**Extraction of cytokines from the stratum corneum**

The fifth consecutive tape strip was used to measure cytokine levels in the SC. To determine the amount of soluble protein and cytokines, 0–6 mL of phosphate-buffered saline (Merck, Darmstadt, Germany) with 0.005% Tween-20 (Sigma-Aldrich, Zwijndrecht, the Netherlands) was added to each vial, and the vials were left on ice for 30 min. Extraction was performed with an ultrasound sonifier equipped with a probe (Salm & Kipp, Breukelen, the Netherlands) for 15 min in ice water. The extract was centrifuged (2 min at 15 000 g), and supernatant aliquots of 60 μL were frozen at \(-80 \, ^\circ C\) until further analysis. The amount of cytokine in the SC was normalized by
the protein content, which was determined using the Pierce Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, U.S.A.), with the bovine serum albumin supplied as standard.

Statistical analysis

All calculations were performed using Prism 7 software (GraphPad, La Jolla, CA, U.S.A.) and R 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). The distribution of data was tested by the Shapiro–Wilk normality test; P-values were corrected for multiple testing using a Benjamini–Hochberg procedure. The applied statistical test is indicated within the figure or the figure legends.

Results

Study patients

We recruited 100 infants with moderate or severe AD and 20 healthy control infants. From this cohort, we analysed plasma of 47 patient samples and 20 control samples. SC samples were analysed for NMF in 74 patient samples and 18 controls, and for cytokines in 66 patient samples and 13 controls. Demographic details of the patients and controls analysed in this study are outlined in Table 1. All raw study data are listed in Tables S2 and S3 (see Supporting Information).

Table 1 Demographic and laboratory details of the study participants

|                      | Patients with AD | Controls |
|----------------------|------------------|----------|
|                      | Plasma | SC | Plasma | SC |
| Total                | 47    | 66 | 20     | 13 |
| Sex                  |        |    |        |    |
| Male                 | 34     | 49 | 14     | 9  |
| Female               | 13     | 17 | 6      | 4  |
| Age (months)         |        |    |        |    |
| Average              | 6.7    | 7  | 6.5    | 6.7|
| Range                | 0–11   | 0–11|0–12|0–12|
| Age at AD onset (weeks) |    |    |        |    |
| Average              | 11.8   | 11 | –      | –  |
| Range                | 2–44   | 2–44|–    | –  |
| SCORAD               |        |    |        |    |
| Average              | 48     | 45.2| –    | –  |
| Range                | 25–91.3| 25–85| –   | –  |
| TEWL (g m$^{-2}$ h$^{-1}$) |    |    |        |    |
| Average              | 26     | 24.1| 11    | 12 |
| Range                | 8.5–53.9| 8.3–53.9| 4–15.6| 8.1–15.6|
| FLG status           |        |    |        |    |
| Wild-type            | 26     | 30 | 18     | 11 |
| Heterozygous         | 18     | 27 | 2      | 2  |
| Homozygous           | 3      | 5  | 0      | 0  |
| Unknown              | 1      | 4  | 0      | 0  |

AD, atopic dermatitis; SC, stratum corneum; SCORAD, Scoring Atopic Dermatitis; TEWL, transepidermal water loss.

Measures of barrier function: unaffected atopic dermatitis skin vs. healthy control skin

Patients with AD had significantly lower NMF levels and higher TEWL readings than healthy controls (Fig. S1; see Supporting Information). TEWL values in patients with AD and healthy controls decreased exponentially with NMF (Fig. 1). TEWL was associated with AD severity scores (Fig. S2; see Supporting Information).

Stratum corneum and systemic biomarkers: atopic dermatitis vs. healthy controls

Nineteen of 27 and 12 of 39 measured biomarkers, in SC and plasma, respectively, showed significantly different levels in infants with AD compared with healthy controls (Fig. 2). While some biomarkers showed directional change (i.e. parallel increase or decrease in patients with AD vs. healthy controls), some of them showed discordance between SC and plasma, or were significantly different only in SC or plasma. For example, CCL17 and CCL22 were elevated in AD in both SC and plasma. However, several inflammatory biomarkers were significantly different from healthy controls only in the SC; these included IL-1α, IL-1β, IL-15, IL-16, IL-18, IL-12p40, SAA; chemokines CXCL8, CCL2 and CCL4; cell adhesion biomarkers sVCAM-1 and sICAM-1 and vascular factors VEGF-A and Flt-1. In contrast, VEGF-C, Tie-2 and CCL13 were significantly elevated in plasma and undetectable or unchanged in the SC (Fig. 2).

The biomarker profiles in plasma and SC not only differed qualitatively but also showed distinct magnitudes of difference. Figure 3 demonstrates the fold changes in SC and plasma biomarkers in infants with AD compared with healthy controls. In the skin compartment the most significantly elevated biomarkers in patients with AD were IL-18, CXCL8, Flt-1, CCL22, CCL17 and sICAM-1. The most significant decreases were observed in IL-15, GM-CSF, CCL4, IL-12p40, IL-1α, IL-13 and IL-5. In plasma, the biomarkers CCL17, IL-5, VEGF-C, GM-CSF and CCL26 had the most significant fold increases in plasma of patients with AD compared with healthy controls, while IL-4 and CXCL10 had the most significant decreases. There was no significant differences in SC or plasma biomarkers following stratification for FLG mutations (Fig. S3; see Supporting Information) or by the clinical presence or absence of bacterial superinfection of AD (data not shown).

Stratum corneum and systemic biomarkers: correlation with skin barrier function and disease severity

Correlation analysis between biomarkers and the biophysical measures of barrier function (TEWL) and AD severity (SCORAD and oSCORAD) are shown in Figure 4. Consistently with the differences found between healthy controls and patients with AD (Figs 2, 3), SC inflammatory biomarkers IL-18, CXCL8, VEGF-A and Flt-1 showed the strongest associations with barrier function and AD severity, followed by...
CCL17, CCL22, sICAM-1 and sVCAM-1. In general, similar strength of biomarker association was obtained with SCORAD and oSCORAD. In plasma, biomarkers involved in the Th2 response, CCL22, CCL17 and CCL11, had the strongest association with barrier function. Other plasma inflammatory biomarkers associated with barrier function were CCL13, IL-16 and IL-17A (Fig. 4). Among plasma biomarkers, CCL22 and TNF-α showed the strongest associations with disease severity (oSCORAD). The skin barrier parameters TEWL and NMF showed significant correlation with disease severity (Fig. 4 and Fig. S2; see Supporting Information).

Discussion

This study is novel in several aspects. We studied a large sample size of treatment-naive infants at initial presentation of moderate-to-severe AD. Our noninvasive technique has clear advantages when studying skin disease in any group, but particularly in infants and children. A diverse range of significantly associated and clinicopathologically relevant biomarkers could be measured in the SC. The skin and systemic compartments had distinct biomarker profiles; the skin compartment in our study reflects cytokines dominant in the outer layers of the SC, whereas the plasma profile reflects both tissue and systemic responses. The SC sampling we employed is, compared with full-thickness biopsy, selective for the epidermis and thus more representative of mature cytokine protein expression in this compartment than whole-biopsy mRNA. The techniques we employed to measure biomarkers require further validation; however, in this exploratory study they have proved promising. The identified biomarkers could broadly be grouped into those critical in innate immune activation, Th2 immune activation and angiogenesis.

The role of innate immune activation in the pathogenesis of infantile AD is supported by our findings of elevated IL-18 and IL-1β in the SC of patients with AD compared with healthy controls. These findings are in keeping with recent reports in early-onset AD, where changes in the innate immune system were already detectable at birth. IL-18 levels were particularly striking in our cohort: they were observed in very high levels in the SC, were the most significantly increased biomarker compared with healthy controls, were strongly associated with barrier function, and also correlated with disease severity. IL-18 is a member of the IL-1 family of cytokines. Elevated expression of serum IL-18 is seen in children and murine models. It has been shown to be elevated in the SC of adults with AD and in the serum of infants and children with AD, correlating with disease activity. We also found CXCL8 (IL-8) to be significantly increased in the SC and correlated with disease severity and barrier dysfunction, further supporting the role of innate activation. The pathomechanistic role of CXCL8 in AD has not been studied. SC levels of CXCL8 have been shown to be closely correlated with SC IL-18; however, their relationship, if any, in AD is unknown.

Many cytokines and chemokines involved in the Th2 response were elevated in our cohort. CCL17 and CCL22 were significantly elevated in both the skin and plasma, had notable fold changes compared with controls, and were significantly correlated with severity and barrier function. CCL17, produced by Th2 cells and keratinocytes, is a key chemokine involved in homing of CCR4-expressing T cells to the skin. CCL17 has been detected in the inflamed skin of patients and in an animal model of AD. Serum CCL17 is strongly correlated with disease severity in patients with AD, including infants, and is the most reliable objective AD biomarker identified to
CCL22 is similar to CCL17 and is a chemoattractant for CCR4-expressing skin-homing T cells.

Meta-analysis of available studies reported a strong correlation coefficient between CCL22 and disease severity in AD. IL-13 was elevated in the plasma of infants with AD. The role of IL-13 has been extensively studied in AD, in both animal models and humans, and its role in AD pathogenesis is well established. The other prototypical type 2 cytokine is IL-4, and its aberrant production has long been associated with atopic disorders. We were unable to detect IL-4 in high enough levels to measure it accurately. IL-13 levels have often been shown to be elevated compared with IL-4 levels in inflamed tissues.

Murine work suggests that this is because primary sources of IL-4 include basophils and conventional Th2 cells, in contrast to tissue Th2 cells and group 2 innate lymphoid cells (ILC2s), which are the major producers of IL-13. The fact that ILC2s produce significant quantities of IL-13, but not IL-4, may explain the quantities and timing of expression of these cytokines.

We demonstrated significantly decreased IL-5 levels in the skin compartment of patients with AD compared with healthy controls, in contrast to significantly increased levels in the plasma that positively correlated with disease severity scores. Th2 cells and mast cells are the major IL-5-producing cells. ILC2s also produce Th2 cytokines, including IL-5. ILC2s are involved in innate immune responses in allergy and
Fig 3. Fold differences between cytokine and chemokine levels in the stratum corneum and in plasma of children with atopic dermatitis (AD), and corresponding cytokine and chemokine levels in healthy children. The results are expressed as the mean \pm SEM. Stratum corneum: n = 66 (AD) and n = 13 (healthy); plasma: n = 47 (AD) and n = 20 (healthy). The fold difference was calculated by dividing the individual cytokine or chemokine level in the SC and plasma of each child with AD by the corresponding mean cytokine or chemokine level in healthy children. Differences in cytokine and chemokine levels between healthy children and children with AD were determined by two-tailed Welch’s t-test or two-tailed Mann–Whitney test (raw data in Table S2; see Supporting Information). Benjamini–Hochberg corrected P-values: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. bFGF, basic fibroblast growth factor; CRP, C-reactive protein; GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; PIGF, placental growth factor; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; Th, T helper cell; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.

© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
infection. Unlike in atopic lung disease, IL-5 has not been studied extensively in AD. Gürkan et al. reported significantly increased serum IL-5 levels in infants with AD compared with controls, but did not demonstrate a correlation with disease severity. Eosinophils constitutively express IL-31RA and release proinflammatory cytokines and chemokines, including IL-1β, IL-6, IL-31, CXCL1, CXCL8, CCL2, CCL18 and CCL26, in response to IL-31. In keeping with elevated IL-5 levels and eosinophil activation, we found elevated levels of CCL2, IL-1β and CXCL8 in the SC.

Fig 4. Spearman correlation coefficients between stratum corneum (tape stripping, TS) and plasma biomarkers and atopic dermatitis severity [Scoring Atopic Dermatitis (SCORAD) and objective SCORAD] and transepidermal water loss (TEWL). Benjamini–Hochberg corrected P-values: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. bFGF, basic fibroblast growth factor; CRP, C-reactive protein; GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; NMF, natural moisturizing factor; PIGF, placental growth factor; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; Th, T helper cell; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.

© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
The third prominent biomarker profile in our cohort identifies angiogenesis and lymphangiogenesis as key processes. Biomarkers for these were significantly elevated in patients compared with controls and correlated with disease severity and barrier function. Angiogenesis is a hallmark of chronic inflammatory skin diseases and plays a role in AD, although this has not been extensively studied.61 Plasma and skin concentrations of VEGF-A are increased in patients with AD compared with controls.62,63 The function of lymphangiogenesis in AD and whether it represents a feasible therapeutic target is unclear.61 It is possible that the biological role of lymphangiogenesis in AD may not be pathogenic, but instead a response to inflammation, attempting to rectify the disease through transportation of allergens and inflammatory cells away from the inflamed skin.64,65

Other biomarkers of note in our cohort were GM-CSF and sICAM-1. GM-CSF levels were diminished in the SC and increased in the plasma of infants with AD in our cohort. Plasma levels negatively correlated with barrier function. GM-CSF is synthesized and released by multiple cutaneous cells including keratinocytes.66

Esaki et al. investigated early-onset pediatric AD biomarkers, using immunohistochemistry and real-time polymerase chain reaction to study skin biopsies from 19 children.28 The children were within 6 months of disease onset, with a mean age of 1-3 years. The authors reported Th17, Th9, Th2 and Th22 activation in both lesional and nonlesional skin and demonstrated significantly higher induction of Th17-related cytokines (IL-17A, IL-19, CCL20, IL-37 and peptidase inhibitor 3) in children with AD compared with adults with AD and control patients.28 We did not demonstrate any statistically significant difference in IL-17A levels in the SC or plasma of patients with AD compared with healthy controls. However, we did find an association between IL-17A levels and barrier function, in keeping with a recent murine study.67 It is notable that in the study of Esaki et al., the statistically significant difference in IL-17A levels in paediatric skin was observed when lesional skin was compared with control children or skin of adults with AD. There was no statistically significant difference observed between IL-17A levels in control children and nonlesional skin in children with AD,28 and hence our IL-17A findings concur with their results.

AD is a ‘multiaxis’ immune disease. It is becoming apparent that different subtypes of the disease are associated with variations in immune profiles. Single-cytokine targeting may not be fully effective in this complex disorder, and multicytokine therapies or combination treatment may prove more effective. Therapeutic options in AD are poised to increase rapidly, along with drug costs. An objective and evidence-based approach with respect to disease severity and therapeutic response will become even more relevant. Combinations of biomarkers with good predictive ability identified by multidimensional data and multivariate analysis may be useful tools in drug selection and justification in our patients with severe AD.

We have demonstrated an SC and plasma biomarker profile for infants with moderate-to-severe AD, a novel study in this age group. Innate immunity, Th2 responses and lymphangiogenesis appear to be important mechanisms in early disease. Further understanding of the predictive abilities of biomarker combinations may have clinical utility in objective severity measurements, disease prognostication and measuring therapeutic responses.

References

1. Williams H, Stewart A, von Mutius E et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008; 121:947–54.
2. Zubereiter T, Lötvall J, Simoons S et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA²LEN review. Allergy 2014; 69:1275–9.
3. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483–94.
4. Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis/pathogenesis. Clin Dermatol 2017; 35:349–53.
5. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441–6.
6. Bieber T, Akdis C, Lauener R et al. Global Allergy Forum and 3rd Davos Declaration 2015: atopic dermatitis/eczema: challenges and opportunities toward precision medicine. Allergy 2016; 71:S88–92.
7. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol 2014; 133:1615–25.
8. Hamid Q, Boguniewicz M, Leung DY. Differential expression and in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94:870–6.
9. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014; 133:769–79.
10. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017; 139(Suppl.):S65–76.
11. Werfel T, Allam JP, Biedermann T et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138:336–49.
12. Czarnecki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Clin Immunol Pract 2014; 2:171–9.
13. Oliva M, Renert-Yuval Y, Guttman-Yassky E. The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol 2016; 16:469–76.
14. Gittler JK, Shenker A, Suárez-Fariñas M et al. Progressive activation of TH1/TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012; 130:1344–54.
15. Thelen T, Langeveld-Wildschut EG, Bihari IC et al. Bifasic response against allergens in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996; 97:828–37.
16. Dhirgra N, Guttman-Yassky E. A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J Invest Dermatol 2014; 134:2071–4.
17. Nogales KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and
keratinocyte-response pathways. Br J Dermatol 2008; 159:1092–102.
18 Rabenhorst A, Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases. Curr Allergy Asthma Rep 2014; 14:423.
19 Lee CH, Yu HS. Biomarkers for itch and disease severity in atopic dermatitis. Curr Probl Dermatol 2011; 41:136–48.
20 Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387:1109–22.
21 Shi B, Bangayan NJ, Curd E et al. The skin microbiome is different in pediatric versus adult atopic dermatitis. J Allergy Clin Immunol 2016; 138:1233–6.
22 Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in pediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011; 25:334–9.
23 Hon KL, Leung TF, Ma KC et al. Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratorymarker of the severity of atopic dermatitis in children. Clin Exp Dermatol 2004; 29:293–9.
24 Leung TF, Ma KC, Hon KL et al. Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. Pediatr Allergy Immunol 2003; 14:396–301.
25 Nakazato J, Kishida M, Kuroiwa R et al. Serum levels of TH2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol 2008; 19:605–13.
26 Cole C, Krobch K, Schurch NJ et al. Filaggrin-stratified transcriptional analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. J Allergy Clin Immunol 2014; 134:82–91.
27 Czarnowicki T, Esaki H, Gonzalez J et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA) + TH2/TH1 cell imbalance, whereas adults acquire CLA + TH22/TC22 cell subsets. J Allergy Clin Immunol 2015; 136:941–51.
28 Esaki H, Brunner PM, Renert-Yuval Y et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol 2016; 138:1639–51.
29 Suárez-Fariñas M, Tintle SJ, Shemmer A et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011; 127:954–64.
30 Thijis JL, Strickland I, Brujinzeel-Koomen CAFM et al. Moving towards endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker identification. J Allergy Clin Immunol 2017; 140:730–7.
31 Hanifin JM, Raika G. Diagnostic features of atopic eczema. Acta Derm Venereol Suppl (Stockh) 1980; 92:44–7.
32 Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186:23–31.
33 Dapic I, Jakasa I, Yau NLH et al. Evaluation of an HPLC method for the determination of natural moisturizing factors in the human stratum corneum. Anal Lett 2013; 46:2133–44.
34 Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin’s fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol 2007; 127:1287–4.
35 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289–300.
36 Thurmann L, Grützmann K, Köls M et al. Early-onset childhood atopic dermatitis is related to NLRP2 repression. J Allergy Clin Immunol 2018; 141:1482–5.
Stratum corneum and systemic biomarkers in infantile AD, M.A. McAleer et al.

56 Plaut M, Pierce JH, Watson CJ et al. Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores. Nature 1989; 339:64–7.
57 Yanagibashi T, Satoh M, Nagai Y et al. Allergic diseases: from bench to clinic – contribution of the discovery of interleukin-5. Cytokine 2017; 85:59–70.
58 Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol 2016; 17:765–74.
59 Gürkan A, Yücel AA, Sönmez C et al. Serum cytokine profiles in infants with atopic dermatitis. Acta Dermato-Venereol Cnout 2016; 24:268–73.
60 Kim JE, Kim JS, Cho DH, Park HJ. Molecular mechanisms of cutaneous inflammatory disorder: atopic dermatitis. Int J Mol Sci 2016; 17:E1234.
61 Varricchi G, Granata F, Loffredo S et al. Angiogenesis and lymphangiogenesis in inflammatory skin disorders. J Am Acad Dermatol 2015; 73:44–53.
62 Brockow K, Akin C, Huber M et al. Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase. J Allergy Clin Immunol 2002; 109:82–8.
63 Zhang Y, Matsuo H, Morita E. Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res 2006; 297:423–9.
64 Akdis CA. Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol 2006; 18:718–26.
65 Huggenberger R, Siddigui SS, Brander D et al. An important role of lymphatic vessel activation in limiting acute inflammation. Blood 2011; 117:4667–78.
66 Ruef C, Coleman DL. Granulocyte–macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990; 12:41–62.
67 Floudas A, Sauber SP, Moran T et al. IL-17 receptor A maintains and protects the skin barrier to prevent allergic skin inflammation. J Immunol 2017; 199:707–17.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Table S1 Cytokine and chemokine limits of detection and number of cytokines with concentrations below the fit curve range in the stratum corneum and in plasma.

Table S2 Cytokine and chemokine levels (log-transformed values) and differences between their levels in the stratum corneum and plasma of healthy control children and children with atopic dermatitis.

Table S3 Correlation (two-tailed Spearman’s test) between cytokines and chemokines (log-transformed values) and (a) Scoring Atopic Dermatitis (SCORAD)/objective SCORAD and (b) transepidermal water loss in the stratum corneum and in plasma of children with atopic dermatitis.

Fig S1. Natural moisturizing factor levels in the stratum corneum, and transepidermal water loss in children with atopic dermatitis and healthy controls.

Fig S2. Linear regression for transepidermal water loss and atopic dermatitis severity [Scoring Atopic Dermatitis (SCORAD) and objective SCORAD] in children with atopic dermatitis.

Fig S3. Levels of cytokines and chemokines, natural moisturizing factor and transepidermal water loss in healthy controls and children with atopic dermatitis stratified for FLG mutations.